natgillin/translations-raw huggingface dataset:
Film coating: Polydextrose (E1200) Titanium dioxide (E171) Hypromellose (E464) Macrogol 4000
Film-ovojnica: polidekstroza (E1200) titanijev dioksid (E171) hipromeloza (E464) makrogol 4000
Film coating: polyvinyl alcohol, titanium dioxide, macrogol, talc, indigo carmine aluminum lake (E 132).
Film ovojnica: poli(vinilni) alkohol, titanijev dioksid, makrogol, talk, boja indigo carmine aluminum lake (E 132).
Film coating; , composed of : polyvinyl alcohol – partly hydrolysed, macrogol / polyethylene glycol 3350, titanium dioxide (E171), talc, iron oxide red, iron oxide yellow, iron oxide black.
Film ovojnica: poli(vinilni alkohol) - djelomično hidrolizirani; makrogol/polietilenglikol 3350; titanijev dioksid (E171); talk; željezov oksid, crveni; željezov oksid žuti; željezov oksid, crni.
Film coating;, composed of : polyvinyl alcohol – partly hydrolysed, macrogol / polyethylene glycol 3350, titanium dioxide (E171), talc, iron oxide red, iron oxide yellow, iron oxide black.
Film ovojnica: poli(vinilni aklohol) - djelomično hidrolizirani, makrogol/polietilenglikol 3350, titanijev dioksid (E171); talk; željezov oksid, crveni; željezov oksid, žuti; željezov oksid, crni.
Film-coat*: hydroxypropylcellulose, hypromellose, propylene glycol and titanium dioxide (E 171).
Film ovojnica*: hidroksipropilceluloza, hipromeloza, propilenglikol i titanijev dioksid (E 171)
Film-coat: Hydroxypropylmethylcellulose Talc
Film ovojnica: hidroksipropilmetilceluloza talk
Film-coat: Hydroxypropylmethylcellulose, Talc
Film ovojnica: hidroksipropilmetilceluloza talk
Film-coat: Hypromellose (E464) Macrogol 8000 Titanium dioxide (E171) Talc
Film ovojnica: hipromeloza (E464) makrogol 8000 titanijev dioksid (E171) talk
Film-coat: hypromellose (E464), titanium dioxide (E171), polyethylene glycol, iron oxide yellow (E172) (for 0.5 mg tablets), polysorbate 80 (E433) and iron oxide red (E172) (for 2 mg tablets).
Film ovojnica: hipromeloza (E464), titanijev dioksid (E171), polietilenglikol, žuti željezov oksid (E172) (za tablete od 0,5 mg), polisorbat 80 (E433) i crveni željezov oksid (E172) (za tablete od 2 mg).
Film-coat: hypromellose, titanium dioxide, black iron oxide (E172), macrogol, polysorbate 80
Film ovojnica: hipromeloza, titanijev dioksid, crni željezov oksid (E172), makrogol, polisorbat 80
Film-coat: hypromellose, titanium dioxide, macrogol, polysorbate 80
Film ovojnica: hipromeloza, titanijev dioksid, makrogol, polisorbat 80
Film-coat: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), iron oxide yellow (E172), triacetin.
Film ovojnica: laktoza hidrat, hipromeloza(E464), titanijev dio ksid (E171), žuti željezov oksid (E172), triacetin.
Film-coat: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), iron oxide yellow (E172), triacetin.
Film ovojnica: laktoza hidrat, hipromeloza(E464), titanijev dio-ksid (E171), žuti željezov oksid (E172), triacetin.
Film-coat: lactose monohydrate, hypromellose, triacetin, titanium dioxide (E171), iron oxide yellow (E172), talc.
Film ovojnica: laktoza hidrat, hipromeloza, triacetin, titanijev dioksid (E171), žuti željezov oksid (E172), talk
Film-coat: poly (vinyl alcohol), titanium dioxide, macrogol 3350, talc, soya lecithin, indigo carmine aluminium lake (E132).
Film ovojnica: poli(vinilni alkohol), titanijev dioksid, makrogol 3350, talk, sojin lecitin, boja "indigo carmine aluminium lake“ (E132).
Film-coat: polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide (E171), colourants*
Film ovojnica: poli(vinilni alkohol), polietilenglikol, talk, titanijev dioksid (E171), bojila
Film-coated
Filmom obložena
Film-coated
filmom obložene
Film-coated (tablet)
Filmom obložena (tableta).
Film-coated tablet
14 tableta
Film-coated tablet
168 tableta
Film-coated tablet
90 tableta
Film-coated tablet
EU/1/10/655/004
Film-coated tablet
EU/1/11/706/029
Film-coated tablet
Filmom
Film-coated tablet
Filmom obložena
Film-coated tablet
Filmom obložena tablea
Film-coated tablet
Filmom obložena tablet
Film-coated tablet
filmom obložena tableta filmom obložena tableta
Film-coated tablet
filmom obložene
Film-coated tablet
filmom obložene tablete filmom obložene tablete
Film-coated tablet
tableta
Film-coated tablet
tableta tableta
Film-coated tablet
tablete
Film-coated tablet (tablet)
Filmom obložena tableta (tableta).
Film-coated tablet (tablet) Inlyta 1 mg film-coated tablets
Filmom obložena tableta (tableta) Inlyta 1 mg filmom obložene tablete
Film-coated tablet (tablet): The tablets are round, biconvex, pink, film-coated marked with a “60” above “T” on one side.
Filmom obložena tableta (tableta): Tablete su okrugle, ispupčene s obje strane, roze, filmom obložene s oznakom "60" iznad slova "T" na jednoj strani.
Film-coated tablet (tablet): The tablets are round, biconvex, yellow, film-coated marked with a “90” above “T” on one side.
Filmom obložena tableta (tableta): Tablete su okrugle, ispupčene s obje strane, žute, filmom obložene s oznakom "90" iznad slova "T" na jednoj strani.
Film-coated tablet (tablets): STAYVEER 62.5 mg film-coated tablets
Filmom obložena tableta (tablete): STAYVEER 62,5 mg filmom obložene tablete
Film-coated tablet (tablets): Tracleer 62.5 mg film-coated tablets
Filmom obložena tableta (tablete): Tracleer 62,5 mg filmom obložene tablete
Film-coated tablet 3 tablets
Filmom obložena tableta 3 tablete
Film-coated tablet 50 mg:
Filmom obložena tableta 50 mg:
Film-coated tablet [tablet].
Filmom obložena tableta [tableta].
Film-coated tablet Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets
Filmom obložena tableta Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete
Film-coated tablet Film-coated tablet
Filmom obložena tableta
Film-coated tablet Film-coated tablet
obložene tablete
Film-coated tablet Film-coated tablet Film-coated tablet
filmom obložena tableta
Film-coated tablet STOCRIN 600 mg film-coated tablets
Filmom obložena tableta STOCRIN 600 mg filmom obložene tablete
Film-coated tablet Wakix 4.5 mg film-coated tablet
Filmom obložena tableta Wakix 4,5 mg filmom obložena tableta
Film-coated tablet.
Filmom obloţena tableta.
Film-coated tablet: yellow, capsule-shaped, film-coated tablet debossed with “Teva” on one side and “7541” on the other
Filmom obložena tableta: žuta filmom obložena tableta oblika kapsule, s oznakom “Teva” na jednoj i “7541” na drugoj strani
Film-coated tablets
Filmom obloženih tableta
Film-coated tablets 14 film-coated tablets
filmom obložene tablete
Film-coated tablets 3 film-coated tablets
Filmom obložene tablete 3 filmom obložene tablete
Film-coated tablets 50 film-coated tablets
filmom obložene tablete
Film-coated tablets 56 film-coated tablets
Filmom obložene tablete
Film-coated tablets and powder for oral suspension
Filmom obložene tablete i prašak za oralnu suspenziju
Film-coated tablets and solution for infusion
Filmom obložene tablete i otopina za infuziju
Film-coated tablets are yellow, oval and scored on one side and are supplied in packs of 10, 20, 30, 50, 60 or 100 film-coated tablets or multipacks of 120 (2 packs of 60) or 200 (2 packs of 100) film- coated tablets.
Filmom obložene tablete su žute, duguljaste tablete s razdjelnom crtom na jednoj strani i dostupne su u pakiranjima od 10, 20, 30, 50, 60 ili 100 filmom obloženih tableta ili višestrukim pakiranjima koja sadrže 120 (2 pakiranja od 60) ili 200 (2 pakiranja od 100) filmom obloženih tableta.
film-coated tablets film-coated tablets
15 filmom obloženih tableta
film-coated tablets film-coated tablets
filmom obloženih tableta filmom obloženih tableta
Film-coated tablets Treatment initiation pack
Filmom obložene tablete Pakiranje za započinjanje liječenja
Film-coated tablets.42 film-coated tablets.
Filmom obložene tablete.
Film-coated, dark red, oval shaped tablet, mentioning T on one side, 800 on the other side.
Tamnocrvena, duguljasta, filmom obložena tableta s oznakom T s jedne strane, a 800 s druge strane.
Film-coated, light orange, oval shaped tablet, mentioning TMC on one side, 400MG on the other side.
Svijetlonarančasta, duguljasta, filmom obložena tableta s oznakom TMC s jedne strane, a 400MG s druge strane.
Film-coated, orange, oval shaped tablet, mentioning TMC on one side, 600MG on the other side.
Narančasta, duguljasta, filmom obložena tableta s oznakom TMC s jedne strane, a 600MG s druge strane.
Film-coated, orange, oval shaped tablet, mentioning TMC114 on one side, 300MG on the other side.
Narančasta, duguljasta, filmom obložena tableta s oznakom TMC 114 s jedne strane, a 300MG s druge strane.
Film-coated, white, caplet shaped tablet, mentioning TMC on one side, 75 on the other side.
Bijela, duguljasta, filmom obložena tableta s oznakom TMC s jedne strane, a 75 s druge strane.
Film-coated, white, oval shaped tablet, mentioning TMC on one side, 150 on the other side.
Bijela, duguljasta, filmom obložena tableta s oznakom TMC s jedne strane, a 150 s druge strane.
Film-coating
Ovojnica tablete
Film-coating - hypromellose (hydroxypropyl methyl cellulose, E464), titanium dioxide (E171), talc (E553b), triacetin (E1518), red iron oxide (E172)
Film ovojnica - hipromeloza (hidroksipropilmetilceluloza, E464), titanijev dioksid (E171), talk (E553b), triacetin (E1518), crveni željezov oksid (E172)
Film-coating Ethylcellulose Hypromellose Macrogol 8000 Triethyl citrate Titanium dioxide Talc
Film ovojnica etilceluloza hipromeloza makrogol 8000 trietilcitrat titanijev dioksid talk
Film-coating for 150 mg/12.5 mg strength: Hypromellose
Film ovojnica tablete od 150 mg/12,5 mg: hipromeloza
Film-coating for 300 mg/12.5 mg strength: Hypromellose
Film ovojnica tablete od 300 mg/12,5 mg: hipromeloza
Film-coating Hypromellose Lactose monohydrate Triacetin
Film ovojnica hipromeloza laktoza hidrat triacetin
Film-coating Hypromellose Titanium dioxide Lactose monohydrate Triacetin
Film ovojnica Hipromeloza titanijev dioksid laktoza hidrat triacetin
Film-coating Hypromellose Titanium dioxide Macrogol 400
Film ovojnica: hipromeloza titanijev dioksid makrogol 400
Film-coating of the 150 mg tablets: hypromellose, titanium dioxide (E171), yellow iron oxide, red iron oxide (E172), talc.
Film ovojnica 150 mg tablete: hipromeloza, titanijev dioksid (E171), žuti i crveni željezov oksid (E172), talk.
Film-coating of the 300 mg tablets: hypromellose, titanium dioxide (E171), talc.
Film ovojnica 300 mg tablete: hipromeloza, titanijev dioksid (E171), talk.
Film-coating of the 500 mg tablets: hypromellose, titanium dioxide (E171), yellow iron oxide, red iron oxide (E172), talc.
Film ovojnica 500 mg tablete: hipromeloza, titanijev dioksid (E171), žuti i crveni željezov oksid (E172), talk.
Film-coating Polyvinyl alcohol Titanium dioxide Macrogol 3350 Talc
Film ovojnica poli(vinilni alkohol) titanijev dioksid makrogol 3350
Film-coating: hypromellose (E464), lactose monohydrate,macrogol/PEG 4000, titanium dioxide (E171).
Film-ovojnica: hipromeloza (E464), laktoza hidrat, makrogol/PEG 4000, titanijev dioksid (E171).
film-coating: hypromellose (E464), titanium dioxide (E171), macrogol (E1521), iron oxide red (E172) and iron oxide black (E172).
Film ovojnica: hipromeloza (E464), titanijev dioksid (E171), makrogol (E1521), crveni željezov oksid (E172) i crni željezov oksid (E172)
Film-coating: hypromellose (E464), titanium dioxide (E171), talc, propylene glycol (E1520) colourants*.
Film-ovojnica: hipromeloza (E464), titanijev dioksid (E171), talk, propilenglikol (E1520), bojila*.
Film-coating: Hypromellose Titanium dioxide
Film ovojnica: hipromeloza titanijev dioksid
Film-coating: hypromellose, titanium dioxide (E171), macrogol 400
Ovojnica tablete: titanijev dioksid (E171), hipromeloza i makrogol 400.
Film-coating: hypromellose, titanium dioxide (E171), macrogol 400
Ovojnica tablete:, titanijev dioksid (E171), hipromeloza i makrogol 400.
Film-coating: hypromellose, titanium dioxide (E171), macrogol 400, indigo carmine aluminum lake (E132), yellow iron oxide (E172)
Film ovojnica: hipromeloza, titanijev dioksid (E171), makrogol 400, boja indigo carmine aluminum lake (E132), žuti željezov oksid (E172)
Film-coating: hypromellose; titanium dioxide; macrogol 400
Film ovojnica: hipromeloza; titanijev dioksid (E 171); makrogol 400
Film-coating: Lactose monohydrate Hypromellose Titanium dioxide Macrogol 3000 Carnauba wax.
Film-ovojnica: laktoza hidrat hipromeloza titanijev dioksid makrogol 3000 karnauba vosak
Film-coating: polyvinyl alcohol (E1203); titanium dioxide (E171); macrogol 3350 (E1521); talc (E553b); iron oxide yellow (E172) and iron oxide red (E172).
Film-ovojnica: polivinilni alkohol (E1203); titanijev dioksid (E171); makrogol 3350 (E1521); talk (E553b); žuti željezov oksid (E172) i crveni željezov oksid (E172).
Film-coating: polyvinyl alcohol (part. hydrolysed), titanium dioxide (E171), macrogol/PEG 3350, talc and indigo carmine aluminium lake (E132).
Film ovojnica: poli(vinilni alkohol) (djelomično hidroliziran), titanijev dioksid (E171),makrogol/PEG3350, talk i indigo carmine aluminium lake (E132).
Film-coating: polyvinyl alcohol, macrogol 3350, titanium dioxide (E171), talc (E553b), iron oxide red (E172), iron oxide yellow (E172)
Film ovojnica: polivinilni alkohol, makrogol 3350, titanijev dioksid (E171), talk (E553b), crveni željezov oksid (E172), žuti željezov oksid (E172)
Film-coating: polyvinyl alcohol, macrogol 3350, titanium dioxide (E171), talc (E553b), iron oxide yellow (E172)
Film ovojnica: polivinilni alkohol, makrogol 3350, titanijev dioksid (E171), talk (E553b), žuti željezov oksid (E172)
Film-coating: polyvinyl alcohol, titanium dioxide (E-171), talc, macrogol 3350 and iron oxide yellow (E- 172)
Film ovojnica: poli(vinilni alkohol), titanijev dioksid (E171), talk, makrogol 3350 i žuti željezov oksid (E172).
Film-coating: polyvinyl alcohol, titanium dioxide (E-171), talc, macrogol 3350, iron oxide yellow (E-172) and iron oxide red (E-172)
Film ovojnica: poli(vinilni alkohol), titanijev dioksid (E171), talk, makrogol 3350, žuti željezov oksid (E172) i crveni željezov oksid (E172).
Film-coating: polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000.
Filmska ovojnica: polivinilni alkohol, titanijev dioksid (E171), crveni željezov oksid (E172), žuti željezov oksid (E172), talk i makrogol 3000.
Film-coating: polyvinyl alcohol; macrogol 3350, titanium dioxide (E171); talc (E553b) and iron oxide yellow (E172).
Film ovojnica: poli(vinilni alkohol); makrogol/3350; titanijev dioksid (E171); talk (E553b) i žuti željezov oksid (E172).
Film-coating: polyvinyl alcohol; macrogol 3350; titanium dioxide (E171); talc (E553b) and iron oxide red (E172).
Film ovojnica: poli(vinilni alkohol); makrogol/3350; titanijev dioksid (E171); talk (E553b) i crveni željezov oksid (E172).
Film-coating: Talc(E553b) Hypromellose (E464) Titanium dioxide (E171) Macrogol 8000
Ovojnica tablete: talk (E553b) hipromeloza (E464) titanijev dioksid (E171)
Filter for MEPACT
Filtar za MEPACT
Filtering can be achieved by following the reconstitution and/or administration steps as described in the package leaflet provided with Kovaltry.
Filtriranje se može postići tako da se slijede koraci za rekonstituciju i/ili primjenu kako je opisano u uputi o lijeku priloženoj uz Kovaltry.
Fimbriae Types 2 and 3 (FIM) 5 micrograms Hepatitis B surface antigen2,3 10 micrograms Poliovirus (Inactivated)4
Fimbrije, tip 2 i 3 (FIM) 5 mikrograma Površinski antigen virusa hepatitisa B 2,3 10 mikrograma poliovirus (neaktiviran)4
Fimbriae Types 2 and 3 (FIM) 5 micrograms Hepatitis B surface antigen2,3 10 micrograms Poliovirus (Inactivated)4
Fimbrije, tip 2 i 3 (FIM) 5 mikrograma Površinski antigen virusa hepatitisa B 2,3 10 mikrograma Virus poliomijelitisa (inaktiviran) 4
FIN-02200 Espoo
FI-02200 Espoo Finska
FIN-02200 ESPOO FINLAND
FIN-02200 ESPOO FINSKA
FIN-02600 Espoo Puh/Tel: + 358 10 2421 hctilaus@fi.aga.com
77772828 ή +357-22482330 info@cy.linde-gas.com
Final
24,1 (11,1 do
Final adult height was available for 14 of those children and demonstrated that 12 continued to show height deficits > 15 percentiles, 10 to 12 years after the end of treatment.
Konačna visina u odrasloj dobi bila je dostupna za 14 navedene djece te se pokazalo da njih 12 i dalje ima deficite rasta za > 15 percentila, 10 do 12 godina nakon završetka liječenja.
Final adult height was available for 14 of those children and show that 12 continued to have height deficits > 15 percentiles, 10 to 12 years after the end of treatment.
Konačna visina u odrasloj dobi bila je dostupna za 14 navedene djece te se pokazalo da njih 12 i dalje ima deficite rasta za > 15 percentila, 10 do 12 godina nakon završetka liječenja.
Final adult height was available for 14 of those children and show that 12 continued to have height deficits > 15 percentiles, 10 to 12 years after the end of treatment.
Konačna visina u odrasloj dobi bila je dostupna za 14 od te djece i pokazala je da ih je 12 nastavilo imati deficit visine > 15 percentila 10 do 12 godina nakon kraja liječenja.
Final analysis4
Završna analiza4
Final Clinical
Završno izvješće
Final clinical study report
Završni izvještaj o kliničkom ispitivanju
Final Clinical study report Q4 2017
Završno izvješće o kliničkom ispitivanju
Final CSR BO22334a (both stages)
Završno Izvješće o kliničkom ispitivanju BO22334 a (oba stadija)
Final CSR BO25341a (both parts)
Završno Izvješće o kliničkom ispitivanju BO25341 a (oba dijela)
Final CSR December 2020
Završno izvješće kliničkog ispitivanja prosinac 2020
Final CSR: 3Q 2017
Završno Izvješće o kliničkom ispitivanju
Final data will be submitted when available.
Kad budu dostupni, predat će se konačni podaci.
Final dose population N=96
Pedijatrijska populacija
Final OS analysis (post-hoc analysis, 07 August 2013)
Završna analiza OS-a (post-hoc analiza, 07. kolovoza 2013.)
Final overall survival (OS) data are presented for Study B. For Study A, OS data were not yet mature at the time of the analysis.
Završni podaci o ukupnom preživljenju (OS) su prikazani za Ispitivanje B. Za Ispitivanje A, OS podaci još nisu bili zreli u vrijeme analize.
Final report 5 years after launch.
Završno izvješće 5 godina nakon stavljanja u promet.
Final report by 2023
Završno izvješće do 2023. godine
Final report:
izvješće: prosinac
Final report: Q4 2018
Završno izvješće: četvrto tromjesečje 2018. godine
final study
izviješće
final study
Predaja
Final study report
PSUR-om
Final study report
Završno izvješće
Final study report by 31 December 2020
Završno izvješće o ispitivanju do 31. prosinca 2020.
Final study report by 31/03/2021
Završno izvješće ispitivanja do 31.03.2021.
Final study report expected in Jan 2027
siječnju 2027
Final study report submission: November 2019
Završno izvješće o ispitivanju podnijeti do: studeni 2019.
Final study report – by Q2 2022.
Konačno izvješće o rezultatu ispitivanja - 2. tromjesečje 2022.
Final study report: June 2016
Završno izvješće iz ispitivanja: lipanj 2016.
Final Study Report: June 2018
Završno izvješće o ispitivanju: lipanj 2018
Final Study Reports submitted by Q4 2020
Završna izvješća o ispitivanju dostaviti do četvrtog kvartala 2020.
Final survival analysis
Završna analiza preživljenja
Final volume of the bottle after reconstitution is 75 ml.
Konačni volumen nakon pripreme iznosi 75 ml.
Finally seal the package with the sticker.
Na kraju zapečatite kutijicu naljepnicom.
Finally seal the package with the sticker.
Na kraju zapečatite kutiju naljepnicom.
Finally the ‘N-dealkylated acid’ (NW-1689) is formed by oxidative cleavage of the amine bond of either safinamide (minor) or the primary safinamide acid metabolite (NW-1153) (major).
Konačno „N-dealkilirana kiselina“ (NW-1689) stvara se oksidativnim cijepanjem aminske veze ili safinamida (manje) ili primarnog metabolita safinamidne kiseline (NW-1153) (znatno).
Finally, a main study in around 4,000 boys and men from 16 to 26 years of age compared the vaccine against placebo to test the vaccine’s effect in preventing genital warts, precancerous anal lesions and anal cancer.
Naposljetku, u glavnom ispitivanju koje je obuhvatilo oko 4 000 mladića i muškaraca u dobi od 16 do 26 godina cjepivo je uspoređeno s placebom kako bi se ispitalo djelovanje cjepiva u sprječavanju genitalnih bradavica, premalignih lezija anusa i raka anusa.
Finally, a main study in around 4,000 boys and men from 16 years of age compared the vaccine with placebo to test the vaccine’s effect in preventing genital warts, precancerous anal lesions and anal cancer.
Naposljetku, u glavnom ispitivanju koje je obuhvatilo oko 4 000 mladića i muškaraca u dobi od 16 do 26 godina cjepivo je uspoređeno s placebom kako bi se ispitalo djelovanje cjepiva u sprječavanju genitalnih bradavica, premalignih lezija i raka anusa.
Finally, Aclasta was more effective than risedronate at increasing spine bone density over a year’s treatment in patients taking glucocorticoids.
Naposljetku, Aclasta je bio djelotvorniji od risedronata u povećanju gustoće kosti kralježnice tijekom jednogodišnje terapije u bolesnika koji su uzimali glukokortikoide.
Finally, as soon as three eggs are close to maturation, a single injection of a hormone called human chorionic gonadotropin (hCG) is given to release the mature eggs.
Naposljetku, čim se tri jajašca bliže sazrijevanju, daje se jedna injekcija hormona naziva ljudski korionski gonadotropin (hCG) za otpuštanje zrelih jajašaca.
Finally, Dafiro HCT must not be used in patients with hypokalaemia (low blood potassium levels), hyponatraemia (low blood sodium levels) and hypercalcaemia (high blood calcium levels) that do not respond to treatment and in patients with hyperuricaemia (high blood levels of uric acid) that causes symptoms.
Naposljetku, Dafiro HCT ne smije se koristiti u bolesnika s hipokalemijom (niskim razinama kalija u krvi), hiponatremijom (niskim razinama natrija u krvi) i hiperkalcemijom (visokim razinama kalcija u krvi) koji ne odgovaraju na liječenje i u bolesnika s hiperurikemijom (visokim razinama mokraćne kiseline) koja uzrokuje simptome.
Finally, in 2 studies of patients with suspected fungal infection who were treated empirically, Cancidas was as effective as amphotericin B. In one of studies involving around 1,000 adults, 34% of patients had a favourable response with either Cancidas or amphotericin B Similar results were seen in the second study, which involved 82 children aged between two and 17 years.
Konačno, u dvama ispitivanjima na bolesnicima s pretpostavljenom gljivičnom infekcijom koji su liječeni empirijski, lijek Cancidas bio je djelotvoran koliko i amfotericin B. U jednom od ispitivanja koje je obuhvatilo 1 000 odraslih osoba, 34 % bolesnika imalo je povoljan odgovor ili na lijek Cancidas ili na amfotericin B. Slični rezultati uočeni su u drugom ispitivanju koje je uključivalo 82 djece u dobi od dvije do 17 godina.
Finally, recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of MabThera have been included in the summary of product characteristics and the package leaflet.
Naposljetku, preporuke i mjere opreza koje zdravstveni radnici i bolesnici trebaju primjenjivati radi sigurne i učinkovite upotrebe lijeka MabThera nalaze se u sažetku opisa svojstava i u uputi o lijeku.
Finally, the company will perform the following studies: a study comparing the benefits of the film- coated tablets with the dispersible tablets; a study in children aged 10 years and above with non- transfusion-dependent thalassaemia to obtain more information on the long-term effects of treatment in these patients; and a study to assess the safety of the film-coated tablets (particularly when they are crushed) in children.
Naposljetku, tvrtka će provesti sljedeća ispitivanja: ispitivanje u okviru kojeg će se usporediti koristi filmom obloženih tableta s tabletama za oralnu suspenziju, ispitivanje na djeci od 10 godina i starijih s talasemijom neovisnom o transfuziji radi dobivanja više informacija o dugoročnim učincima liječenja u takvih bolesnika i ispitivanje u okviru kojega će se ocijeniti sigurnost filmom obloženih tableta u djece (osobito kada su zdrobljene).
Finally, the MAH has proposed minor amendments to the list of adverse reactions in section 4.8 of the SmPC in order to ensure consistency in how these reactions are coded.
Naposljetku, nositelj odobrenja je predložio manje izmjene popisa nuspojava u dijelu 4.8 Sažetka opisa svojstava lijeka zbog osiguravanja dosljednosti u kodiranju nuspojava.